https://www.targetedonc.com/view/emerging-frontiers-in-immunotherapy-the-promise-of-nk-cell-therapies
We got a mention.
The phase 1b ADVENT-AML trial is exploring the use of allogeneic NK cells in combination with azacitidine and venetoclax (Venclexta) in patients with newly diagnosed AML (NCT05834244). The synergy of the regimen allows for upregulation of silenced NKG2D ligands, priming of leukemia cells, and reduction of disease burden.17
https://www.targetedonc.com/view/emerging-frontiers-in-immunother...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $27.11K | 6.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 26897271 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 598021 | 2 |
View Market Depth
| Last trade - 11.20am 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |